Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Questcor Pharmaceuticals

Share:
Related QCOR
BioTime CEO Explains What Could Happen To Stem Cell Research And The Company Under A New Guard In Washington
Mallinckrodt Is No Valeant-Philidor Situation, Morgan Stanley Says

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Questcor Pharmaceuticals (NASDAQ: QCOR), and raised its price target from $28.00 to $30.00.

Jefferies noted, “QCOR beat Q3 revenue and GAAP EPS consensus driven by higher Acthar sales and lower OpEx. Curiously, mgmt has decided to end its monthly disclosure of Acthar Rx citing sales have reached a ‘mature' level, however, mgmt will allow pharmacy distributors to release Rx data to third party providers. We are raising our PT to $30 on lower OpEx and share count, offset by a slight decrease in Acthar sales.”

Questcor Pharmaceuticals closed on Tuesday at $25.93.

Latest Ratings for QCOR

DateFirmActionFromTo
May 2014MizuhoDowngradesBuyNeutral
May 2014PiperJaffrayDowngradesOverweightNeutral
Apr 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for QCOR
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (QCOR)

View Comments and Join the Discussion!
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Aegerion Pharmaceuticals

UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on Gilead Sciences